Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients-Reference-Cited by-同舟云学术

Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients

Published:2013-04-23 Issue:6 Volume:90 Page:486-493
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Wu Lingyun¹,Li Xiao¹,Xu Feng¹,Zhang Zheng¹,Chang Chunkang¹,He Qi¹

Affiliation:

1. Hematology Division; Sixth Hospital Affiliated to Shanghai Jiaotong University; Shanghai; China

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12105/fullpdf

Reference25 articles.

1. The 5q-syndrome;Boultwood;Blood,1994

2. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31;Giagounidis;Leukemia,2004

3. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology;Pellagatti;Br J Haematol,2004

4. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome;Boultwood;Br J Haematol,2007

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparation of ribosomal protein S14 polyclonal antibody in broiler pulmonary artery: Its application in broiler ascites syndrome;International Journal of Biological Macromolecules;2021-12

2. The effect of miR-223 on cellular behaviour in non-5q myelodysplastic syndromes through targeting RPS14;Pathology;2020-08

3. Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years;Expert Review of Anticancer Therapy;2020-06-01

4. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach;Expert Opinion on Investigational Drugs;2019-10-22

5. Introductory Chapter: Progress in Myelodysplastic Syndrome Area;Recent Developments in Myelodysplastic Syndromes;2019-02-20